Skip to main content
Top
Published in: Pituitary 2/2009

01-06-2009

The effects of hyperprolactinemia on bone and fat

Authors: Amal Shibli-Rahhal, Janet Schlechte

Published in: Pituitary | Issue 2/2009

Login to get access

Abstract

Many patients with prolactin secreting pituitary tumors have decreased bone mineral. The bone loss is associated with an increase in bone resorption and is secondary to prolactin-induced hypogonadism. In both sexes trabecular bone in the spine and hip is more affected than cortical bone in the distal radius. Normalization of prolactin and restoration of gonadal function increases bone density but is not associated with normalization of bone mass. It is not known whether the bone loss in hyperprolactinemic subjects represents a failure to achieve peak bone mass or is due to accelerated bone loss. Despite low bone density hyperprolactinemic subjects do not demonstrate increased fractures. The association between prolactin, weight gain and obesity suggests that prolactin may also be a modulator of body composition and body weight. It is not known whether hyperprolactinemia associated weight gain is due to stimulation of lipogenesis or due to disruption of central nervous system dopaminergic tone. Hyperprolactinemia is also associated with insulin resistance and endothelial dysfunction which may improve after normalization of prolactin. The clinical significance of these findings and the precise role of prolactin in regulation of weight and metabolism remain to be elucidated.
Literature
3.
go back to reference Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW (1980) Decreased bone density in hyperprolactinemic women. N Engl J Med 303:1511–1514, MedlinePubMedCrossRef Klibanski A, Neer RM, Beitins IZ, Ridgway EC, Zervas NT, McArthur JW (1980) Decreased bone density in hyperprolactinemic women. N Engl J Med 303:1511–1514, MedlinePubMedCrossRef
4.
go back to reference Schlechte JA, Sherman B, Martin R (1983) Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab 56:1120–1123, MedlinePubMed Schlechte JA, Sherman B, Martin R (1983) Bone density in amenorrheic women with and without hyperprolactinemia. J Clin Endocrinol Metab 56:1120–1123, MedlinePubMed
5.
go back to reference Koppelman MC, Kurtz DW, Morrish KA et al (1984) Vertebral body bone mineral content in hyperprolactinemic women. J Clin Endocrinol Metab 59:1050–1053, MedlinePubMed Koppelman MC, Kurtz DW, Morrish KA et al (1984) Vertebral body bone mineral content in hyperprolactinemic women. J Clin Endocrinol Metab 59:1050–1053, MedlinePubMed
7.
go back to reference Caraceni MP, Corghi E, Ortolani S, Casazza S, D’Alberton A, Motta T (1985) Increased forearm bone mineral content after bromocriptine treatment in hyperprolactinemia. Calcif Tissue Int 37:687–689, Medline. doi:10.1007/BF02554932 PubMedCrossRef Caraceni MP, Corghi E, Ortolani S, Casazza S, D’Alberton A, Motta T (1985) Increased forearm bone mineral content after bromocriptine treatment in hyperprolactinemia. Calcif Tissue Int 37:687–689, Medline. doi:10.​1007/​BF02554932 PubMedCrossRef
8.
go back to reference Klibanski A, Greenspan SL (1986) Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 315:542–546, MedlinePubMedCrossRef Klibanski A, Greenspan SL (1986) Increase in bone mass after treatment of hyperprolactinemic amenorrhea. N Engl J Med 315:542–546, MedlinePubMedCrossRef
9.
go back to reference Greenspan SL, Neer RM, Ridgway EC, Klibanski A (1986) Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med 104:777–782, MedlinePubMed Greenspan SL, Neer RM, Ridgway EC, Klibanski A (1986) Osteoporosis in men with hyperprolactinemic hypogonadism. Ann Intern Med 104:777–782, MedlinePubMed
10.
go back to reference Schlechte J, el-Khoury G, Kathol M, Walkner L (1987) Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 64:1021–1026, MedlinePubMed Schlechte J, el-Khoury G, Kathol M, Walkner L (1987) Forearm and vertebral bone mineral in treated and untreated hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 64:1021–1026, MedlinePubMed
11.
go back to reference Ciccarelli E, Savino L, Carlevatto V, Bertagna A, Isaia GC, Camanni F (1988) Vertebral bone density in non-amenorrhoeic hyperprolactinaemic women. Clin Endocrinol (Oxf) 28:1–6 Ciccarelli E, Savino L, Carlevatto V, Bertagna A, Isaia GC, Camanni F (1988) Vertebral bone density in non-amenorrhoeic hyperprolactinaemic women. Clin Endocrinol (Oxf) 28:1–6
12.
go back to reference Nyström E, Leman J, Lundberg PA et al (1988) Bone mineral content in normally menstruating women with hyperprolactinaemia. Horm Res 29:214–217, MedlinePubMedCrossRef Nyström E, Leman J, Lundberg PA et al (1988) Bone mineral content in normally menstruating women with hyperprolactinaemia. Horm Res 29:214–217, MedlinePubMedCrossRef
13.
go back to reference Klibanski A, Biller BM, Rosenthal DI, Schoenfeld DA, Saxe V (1988) Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 67:124–130, MedlinePubMed Klibanski A, Biller BM, Rosenthal DI, Schoenfeld DA, Saxe V (1988) Effects of prolactin and estrogen deficiency in amenorrheic bone loss. J Clin Endocrinol Metab 67:124–130, MedlinePubMed
14.
go back to reference Greenspan SL, Oppenheim DS, Klibanski A (1989) Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 110:526–531, MedlinePubMed Greenspan SL, Oppenheim DS, Klibanski A (1989) Importance of gonadal steroids to bone mass in men with hyperprolactinemic hypogonadism. Ann Intern Med 110:526–531, MedlinePubMed
15.
go back to reference Sartorio A, Conti A, Ambrosi B, Muratori M, Morabito F, Faglia G (1990) Osteocalcin levels in patients with microprolactinoma before and during medical treatment. J Endocrinol Invest 13:419–422, MedlinePubMed Sartorio A, Conti A, Ambrosi B, Muratori M, Morabito F, Faglia G (1990) Osteocalcin levels in patients with microprolactinoma before and during medical treatment. J Endocrinol Invest 13:419–422, MedlinePubMed
16.
go back to reference Biller BM, Baum HB, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A (1992) Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 75:692–697, Medline. doi:10.1210/jc.75.3.692 PubMedCrossRef Biller BM, Baum HB, Rosenthal DI, Saxe VC, Charpie PM, Klibanski A (1992) Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J Clin Endocrinol Metab 75:692–697, Medline. doi:10.​1210/​jc.​75.​3.​692 PubMedCrossRef
17.
18.
go back to reference Kayath MJ, Lengyel AM, Vieira JG (1993) Prevalence and magnitude of osteopenia in patients with prolactinoma. Braz J Med Biol Res 26:933–941, MedlinePubMed Kayath MJ, Lengyel AM, Vieira JG (1993) Prevalence and magnitude of osteopenia in patients with prolactinoma. Braz J Med Biol Res 26:933–941, MedlinePubMed
19.
20.
21.
go back to reference Colao A, Di Somma C, Loche S, Di Sarno A, Klain M, Pivonello R, Pietrosante M, Salvatore M, Lombardi G (2000) Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf) 52:319–327 Colao A, Di Somma C, Loche S, Di Sarno A, Klain M, Pivonello R, Pietrosante M, Salvatore M, Lombardi G (2000) Prolactinomas in adolescents: persistent bone loss after 2 years of prolactin normalization. Clin Endocrinol (Oxf) 52:319–327
22.
go back to reference Naliato EC, Farias ML, Braucks GR, Costa FS, Zylberberg D, Violante AH (2005) Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest 28:12–17, MedlinePubMed Naliato EC, Farias ML, Braucks GR, Costa FS, Zylberberg D, Violante AH (2005) Prevalence of osteopenia in men with prolactinoma. J Endocrinol Invest 28:12–17, MedlinePubMed
24.
go back to reference Bikle DD, Spencer EM, Burke WH, Rost CR (1980) Prolactin but not growth hormone stimulates 1,25-dihydroxyvitamin D3 production by chick renal preparations in vitro. Endocrinology 107:81–84, MedlinePubMed Bikle DD, Spencer EM, Burke WH, Rost CR (1980) Prolactin but not growth hormone stimulates 1,25-dihydroxyvitamin D3 production by chick renal preparations in vitro. Endocrinology 107:81–84, MedlinePubMed
27.
28.
go back to reference Kumar R, Abboud CF, Riggs BL (1980) The effect of elevated prolactin levels on plasma 1,25-dihydroxyvitamin D and intestinal absorption of calcium. Mayo Clin Proc 55:51–53, MedlinePubMed Kumar R, Abboud CF, Riggs BL (1980) The effect of elevated prolactin levels on plasma 1,25-dihydroxyvitamin D and intestinal absorption of calcium. Mayo Clin Proc 55:51–53, MedlinePubMed
29.
go back to reference Adams ND, Garthwaite TL, Gray RW, Hagen TC, Lemann J Jr (1979) The interrelationships among prolactin, 1,25-dihydroxyvitamin D, and parathyroid hormone in humans. J Clin Endocrinol Metab 49:628–630, MedlinePubMed Adams ND, Garthwaite TL, Gray RW, Hagen TC, Lemann J Jr (1979) The interrelationships among prolactin, 1,25-dihydroxyvitamin D, and parathyroid hormone in humans. J Clin Endocrinol Metab 49:628–630, MedlinePubMed
30.
go back to reference Brown DJ, Spanos E, MacIntyre I (1980) Role of pituitary hormones in regulating renal vitamin D metabolism in man. BMJ 280:277–278, MedlinePubMedCrossRef Brown DJ, Spanos E, MacIntyre I (1980) Role of pituitary hormones in regulating renal vitamin D metabolism in man. BMJ 280:277–278, MedlinePubMedCrossRef
31.
go back to reference Genant HK, Cann CE, Ettinger B, Gordon GS (1982) Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med 97:699–705, MedlinePubMed Genant HK, Cann CE, Ettinger B, Gordon GS (1982) Quantitative computed tomography of vertebral spongiosa: a sensitive method for detecting early bone loss after oophorectomy. Ann Intern Med 97:699–705, MedlinePubMed
32.
go back to reference Steinberg KK, Freni-Titulaer LW, DePuey EG et al (1989) Sex steroids and bone density in premenopausal and perimenopausal women. J Clin Endocrinol Metab 69:533–539, MedlinePubMed Steinberg KK, Freni-Titulaer LW, DePuey EG et al (1989) Sex steroids and bone density in premenopausal and perimenopausal women. J Clin Endocrinol Metab 69:533–539, MedlinePubMed
33.
go back to reference Warren MP, Brooks-Gunn J, Fox RP, Lancelot C, Newman D, Hamilton WG (1991) Lack of bone accretion and amenorrhea: evidence for a relative osteopenia in weight bearing bones. J Clin Endocrinol Metab 72:847–853, MedlinePubMed Warren MP, Brooks-Gunn J, Fox RP, Lancelot C, Newman D, Hamilton WG (1991) Lack of bone accretion and amenorrhea: evidence for a relative osteopenia in weight bearing bones. J Clin Endocrinol Metab 72:847–853, MedlinePubMed
34.
go back to reference Biller BM, Coughlin JF, Saxe V, Schoenfeld D, Spratt DI, Klibanski A (1991) Osteopenia in women with hypothalamic amenorrhea: a prospective study. Obstet Gynecol 78:996–1001, MedlinePubMed Biller BM, Coughlin JF, Saxe V, Schoenfeld D, Spratt DI, Klibanski A (1991) Osteopenia in women with hypothalamic amenorrhea: a prospective study. Obstet Gynecol 78:996–1001, MedlinePubMed
35.
go back to reference Bachrach LK, Katzman DK, Litt IF, Guido D, Marcus R (1991) Recovery from osteopenia in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 72:602–606, MedlinePubMed Bachrach LK, Katzman DK, Litt IF, Guido D, Marcus R (1991) Recovery from osteopenia in adolescent girls with anorexia nervosa. J Clin Endocrinol Metab 72:602–606, MedlinePubMed
36.
37.
40.
go back to reference Byatt JC, Staten NR, Salsgiver WJ, Kostelc JG, Collier RJ (1993) Stimulation of food intake and weight gain in mature female rats by bovine prolactin and bovine growth hormone. Am J Physiol (Endocrinol Metab. 27) 264:E986–E992 Byatt JC, Staten NR, Salsgiver WJ, Kostelc JG, Collier RJ (1993) Stimulation of food intake and weight gain in mature female rats by bovine prolactin and bovine growth hormone. Am J Physiol (Endocrinol Metab. 27) 264:E986–E992
41.
go back to reference Galluzi F, Salti R, Stagi S, La Cauza F, Chiarelli F (2005) Reversible weight gain and prolactin levels—long-term follow-up in childhood. J Pediatr Endocrinol Metab 18:921–924, Medline Galluzi F, Salti R, Stagi S, La Cauza F, Chiarelli F (2005) Reversible weight gain and prolactin levels—long-term follow-up in childhood. J Pediatr Endocrinol Metab 18:921–924, Medline
42.
go back to reference Creemers LB, Zelissen PM, van’t Verlaat JW, Koppeschaar HP (1991) Prolactinoma and body weight: a retrospective study. Acta Endocrinol (Copenh) 125:392–396 Creemers LB, Zelissen PM, van’t Verlaat JW, Koppeschaar HP (1991) Prolactinoma and body weight: a retrospective study. Acta Endocrinol (Copenh) 125:392–396
43.
46.
go back to reference Ferreira MF, Sobrinho LG, Santos MA, Sousa MFF, Uvnäs-Moberg K (1998) Rapid weight gain, at least in some women, is an expression of a neuroendocrine state characterized by reduced hypothalamic dopaminergic tone. Psychoneuroendocrinology 23:1005–1013, Medline. doi:10.1016/S0306-4530(98)00063-8 PubMedCrossRef Ferreira MF, Sobrinho LG, Santos MA, Sousa MFF, Uvnäs-Moberg K (1998) Rapid weight gain, at least in some women, is an expression of a neuroendocrine state characterized by reduced hypothalamic dopaminergic tone. Psychoneuroendocrinology 23:1005–1013, Medline. doi:10.​1016/​S0306-4530(98)00063-8 PubMedCrossRef
47.
go back to reference Schmid C, Goede DL, Hauser RS, Brändle M (2006) Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly 138:254–258 Schmid C, Goede DL, Hauser RS, Brändle M (2006) Increased prevalence of high body mass index in patients presenting with pituitary tumours: severe obesity in patients with macroprolactinoma. Swiss Med Wkly 138:254–258
49.
go back to reference Wallace RB, Sherman BM, Bean JA (1985) Clinical and biologic antecedents of the amenorrhea/hyperprolactinemia syndrome: a case control study. Fertil Steril 43:726–732, MedlinePubMed Wallace RB, Sherman BM, Bean JA (1985) Clinical and biologic antecedents of the amenorrhea/hyperprolactinemia syndrome: a case control study. Fertil Steril 43:726–732, MedlinePubMed
50.
52.
55.
go back to reference Cavagnini F, Maraschini C, Pinto M, Dubini A, Polli EE (1981) Impaired prolactin secretion in obese patients. J Endocrinol Invest 4:149–153, MedlinePubMed Cavagnini F, Maraschini C, Pinto M, Dubini A, Polli EE (1981) Impaired prolactin secretion in obese patients. J Endocrinol Invest 4:149–153, MedlinePubMed
56.
go back to reference Amatruda JM, Hochstein M, Hsu TH, Lockwood DH (1982) Hypothalamic and pituitary dysfunction in obese males. Int J Obes 6:183–189, MedlinePubMed Amatruda JM, Hochstein M, Hsu TH, Lockwood DH (1982) Hypothalamic and pituitary dysfunction in obese males. Int J Obes 6:183–189, MedlinePubMed
57.
go back to reference Weaver JU, Noonan K, Kopelman PG, Coste M (1990) Impaired prolactin secretion and body fat distribution in obesity. Clin Endocrinol (Oxf) 32:641–646, MedlineCrossRef Weaver JU, Noonan K, Kopelman PG, Coste M (1990) Impaired prolactin secretion and body fat distribution in obesity. Clin Endocrinol (Oxf) 32:641–646, MedlineCrossRef
58.
go back to reference Weaver JU, Noonan K, Kopelman PG (1991) An association between hypothalamic–pituitary dysfunction and peripheral endocrine function in extreme obesity. Clin Endocrinol (Oxf) 35:97–102, MedlineCrossRef Weaver JU, Noonan K, Kopelman PG (1991) An association between hypothalamic–pituitary dysfunction and peripheral endocrine function in extreme obesity. Clin Endocrinol (Oxf) 35:97–102, MedlineCrossRef
60.
go back to reference Kopelman PG, Pilkington TRE, White N, Jeffcoate SL (1980) Persistence of abnormal hypothalamic control of prolactin secretion in some obese women after weight reduction. BMJ 281:358–359, MedlinePubMedCrossRef Kopelman PG, Pilkington TRE, White N, Jeffcoate SL (1980) Persistence of abnormal hypothalamic control of prolactin secretion in some obese women after weight reduction. BMJ 281:358–359, MedlinePubMedCrossRef
62.
go back to reference Baptista T, Alastre T, Contreras Q et al (1997) Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy men: relationship with body weight regulation. Pharmacopsychiatry 30:250–255, MedlinePubMedCrossRef Baptista T, Alastre T, Contreras Q et al (1997) Effects of the antipsychotic drug sulpiride on reproductive hormones in healthy men: relationship with body weight regulation. Pharmacopsychiatry 30:250–255, MedlinePubMedCrossRef
63.
go back to reference Baptista T, Lacruz A, Meza T et al (2001) Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatry 46:829–834, MedlinePubMed Baptista T, Lacruz A, Meza T et al (2001) Antipsychotic drugs and obesity: is prolactin involved? Can J Psychiatry 46:829–834, MedlinePubMed
64.
go back to reference Baptista T, Parada M, Hernandez L (1987) Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? Pharmacol Biochem Behav 27:399–405, Medline. doi:10.1016/0091-3057(87)90340-6 CrossRef Baptista T, Parada M, Hernandez L (1987) Long term administration of some antipsychotic drugs increases body weight and feeding in rats. Are D2 dopamine receptors involved? Pharmacol Biochem Behav 27:399–405, Medline. doi:10.​1016/​0091-3057(87)90340-6 CrossRef
65.
go back to reference Ling C, Svensson L, Odén B et al (2003) Identification of functional prolactin (PRL] gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab 88:1804–1808, Medline. doi:10.1210/jc.2002-021137 PubMedCrossRef Ling C, Svensson L, Odén B et al (2003) Identification of functional prolactin (PRL] gene expression: PRL inhibits lipoprotein lipase activity in human white adipose tissue. J Clin Endocrinol Metab 88:1804–1808, Medline. doi:10.​1210/​jc.​2002-021137 PubMedCrossRef
66.
67.
go back to reference Highman TJ, Friedman JE, Huston LP, Wong WW, Catalano PM (1998) Longitudinal changes in maternal serum leptin concentrations, body composition, and resting metabolic rate in pregnancy. Am J Obstet Gynecol 178:1010–1015, Medline. doi:10.1016/S0002-9378(98)70540-X PubMedCrossRef Highman TJ, Friedman JE, Huston LP, Wong WW, Catalano PM (1998) Longitudinal changes in maternal serum leptin concentrations, body composition, and resting metabolic rate in pregnancy. Am J Obstet Gynecol 178:1010–1015, Medline. doi:10.​1016/​S0002-9378(98)70540-X PubMedCrossRef
69.
71.
go back to reference Pelkonen R, Nikkilä EA, Grahne B (1982) Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin Endocrinol (Oxf) 16:383–390, MedlineCrossRef Pelkonen R, Nikkilä EA, Grahne B (1982) Serum lipids, postheparin plasma lipase activities and glucose tolerance in patients with prolactinoma. Clin Endocrinol (Oxf) 16:383–390, MedlineCrossRef
72.
go back to reference Schernthaner G, Prager R, Punzengruber C, Luger A (1985) Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 28:138–142, MedlinePubMed Schernthaner G, Prager R, Punzengruber C, Luger A (1985) Severe hyperprolactinemia is associated with decreased insulin binding in vitro and insulin resistance in vivo. Diabetologia 28:138–142, MedlinePubMed
73.
go back to reference Foss MC, Paula FJ, Paccola GM, Piccinato CE (1995) Peripheral glucose metabolism in human hyperprolactinemia. Clin Endocrinol (Oxf) 43:721–726, MedlineCrossRef Foss MC, Paula FJ, Paccola GM, Piccinato CE (1995) Peripheral glucose metabolism in human hyperprolactinemia. Clin Endocrinol (Oxf) 43:721–726, MedlineCrossRef
74.
go back to reference Gustafson AB, Banasiak MF, Kalkhoff RK, Hagen TC, Kim HJ (1980) Correlation of hyperprolactinemia with altered plasma insulin and glucagon: similarity to effects of late human pregnancy. J Clin Endocrinol Metab 51:242–246, MedlinePubMedCrossRef Gustafson AB, Banasiak MF, Kalkhoff RK, Hagen TC, Kim HJ (1980) Correlation of hyperprolactinemia with altered plasma insulin and glucagon: similarity to effects of late human pregnancy. J Clin Endocrinol Metab 51:242–246, MedlinePubMedCrossRef
75.
go back to reference Serri O, Beauregard H, Rasio E, Hardy J (1986) Decreased sensitivity to insulin in women with microprolactinomas. Fertil Steril 45:572–574, MedlinePubMed Serri O, Beauregard H, Rasio E, Hardy J (1986) Decreased sensitivity to insulin in women with microprolactinomas. Fertil Steril 45:572–574, MedlinePubMed
76.
go back to reference Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S (2003) Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 26:341–346, MedlinePubMed Tuzcu A, Bahceci M, Dursun M, Turgut C, Bahceci S (2003) Insulin sensitivity and hyperprolactinemia. J Endocrinol Invest 26:341–346, MedlinePubMed
77.
go back to reference Serri O, Ling L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 64:366–370, Medline Serri O, Ling L, Mamputu JC, Beauchamp MC, Maingrette F, Renier G (2006) The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. Clin Endocrinol (Oxf) 64:366–370, Medline
81.
82.
go back to reference Khosla S, Atkinson EJ, Dunstan CR, O’Fallon WM (2002) Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 87:1550–1554, Medline. doi:10.1210/jc.87.4.1550 PubMedCrossRef Khosla S, Atkinson EJ, Dunstan CR, O’Fallon WM (2002) Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men. J Clin Endocrinol Metab 87:1550–1554, Medline. doi:10.​1210/​jc.​87.​4.​1550 PubMedCrossRef
83.
go back to reference Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ (2007) Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 92:4254–4259, Medline. doi:10.1210/jc.2007-0454 PubMedCrossRef Yialamas MA, Dwyer AA, Hanley E, Lee H, Pitteloud N, Hayes FJ (2007) Acute sex steroid withdrawal reduces insulin sensitivity in healthy men with idiopathic hypogonadotropic hypogonadism. J Clin Endocrinol Metab 92:4254–4259, Medline. doi:10.​1210/​jc.​2007-0454 PubMedCrossRef
88.
go back to reference Meier AH, Cincotta AH, Lovell WC (1992) Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia 48:248–253, Medline. doi:10.1007/BF01930467 PubMedCrossRef Meier AH, Cincotta AH, Lovell WC (1992) Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia 48:248–253, Medline. doi:10.​1007/​BF01930467 PubMedCrossRef
90.
go back to reference Kamath V, Jones CN, Yip JC et al (1997) Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose. Insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemia women. Diabetes Care 20:1697–1701, Medline. doi:10.2337/diacare.20.11.1697 Kamath V, Jones CN, Yip JC et al (1997) Effects of a quick-release form of bromocriptine (Ergoset) on fasting and postprandial plasma glucose. Insulin, lipid, and lipoprotein concentrations in obese nondiabetic hyperinsulinemia women. Diabetes Care 20:1697–1701, Medline. doi:10.​2337/​diacare.​20.​11.​1697
91.
Metadata
Title
The effects of hyperprolactinemia on bone and fat
Authors
Amal Shibli-Rahhal
Janet Schlechte
Publication date
01-06-2009
Publisher
Springer US
Published in
Pituitary / Issue 2/2009
Print ISSN: 1386-341X
Electronic ISSN: 1573-7403
DOI
https://doi.org/10.1007/s11102-008-0097-3

Other articles of this Issue 2/2009

Pituitary 2/2009 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.